NCT04925193View on ClinicalTrials.gov

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

August 6, 2026

Study Completion Date

November 30, 2026

Conditions
Multiple Myeloma in Relapse
Interventions
DRUG

Selinexor

Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).

DRUG

Pomalidomide

Oral Table

DRUG

Daratumumab

Injection

DRUG

Carfilzomib

Injection

DRUG

Dexamethasone

Oral tablet or injection

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Colorado, Denver

OTHER